The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The role of maintenance strategy in metastatic colorectal cancer (mCRC): A systematic review and meta-analysis.
 
Mohamad Bassam Sonbol
No Relationships to Disclose
 
Luke Mountjoy
No Relationships to Disclose
 
Belal Firwana
No Relationships to Disclose
 
Diana Almader-Douglas
No Relationships to Disclose
 
Kabir Mody
Consulting or Advisory Role - AstraZeneca; Celgene; Eisai; Genentech/Roche; Merrimack; Vicus Therapeutics
Research Funding - Agios; ARIAD; ArQule; FibroGen; MedImmune; Senhwa Biosciences; Taiho Pharmaceutical; TRACON Pharma
 
Joleen Marie Hubbard
Consulting or Advisory Role - Genentech/Roche (Inst)
Research Funding - Bayer (Inst); Boston Biomedical (Inst); eFFECTOR Therapeutics (Inst); Merck (Inst); Senhwa Biosciences (Inst); Taiho Pharmaceutical (Inst); Treos Bio (Inst)
 
Mitesh J. Borad
Stock and Other Ownership Interests - AVEO; Gilead Sciences; GlaxoSmithKline
Consulting or Advisory Role - Agios (Inst); ArQule (Inst); Celgene (Inst); Fujifilm (Inst); G1 Therapeutics; Halozyme (Inst); Inspyr Therapeutics; Insys Therapeutics (Inst); Novartis (Inst); Pieris Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); TD2
Research Funding - Agios (Inst); ARIAD (Inst); BiolineRx (Inst); Boston Biomedical (Inst); Celgene (Inst); Dicerna (Inst); Eisai (Inst); EMD Serono (Inst); Halozyme (Inst); ImClone Systems (Inst); Incyte (Inst); Incyte (Inst); Isis Pharmaceuticals (Inst); MedImmune (Inst); miRNA Therapeutics (Inst); Puma Biotechnology (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Senhwa Biosciences (Inst); Sillajen (Inst); Sun Biopharma (Inst); Sun Biopharma (Inst); Taiho Pharmaceutical (Inst); Threshold Pharmaceuticals (Inst); Toray Industries (Inst)
Travel, Accommodations, Expenses - ArQule; AstraZeneca; Celgene
 
Daniel H. Ahn
Consulting or Advisory Role - Astellas Pharma; Cardinal Health; Celltrion (I); Eisai; Lexicon; Merrimack; Paradigm
 
M. Hassan Murad
No Relationships to Disclose
 
Tanios S. Bekaii-Saab
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; Bayer (Inst); Boehringer Ingelheim; Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Celgene; Celgene (Inst); Genentech/Roche; Glenmark; Immuneering; Imugene; Incyte (Inst); Ipsen (Inst); Lilly; Lilly (Inst); Merck (Inst); NCCN; Pfizer; Regeneron; Roche/Genentech (Inst); Sirtex Medical; Taiho Pharmaceutical
Research Funding - NCCN; NCI; Oncolytics
Other Relationship - ARMO BioSciences; Exelixis; Exelixis; Merck; Polaris; Sillajen